DMN:FRA
Diamyd Medical AB
€ ०.०६३
०.००%
(०.००) 1D
नोभेम्बर १९, २२:००:०० GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१४.२२ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१४.२२ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
The Motley Fool
·
३८ मिनेट पहिले
The Semiconductor ETF Is on Track to Beat the S&P 500 for a 4th Straight Year. It Has Never Done That Before.
Yahoo Finance
·
१ घण्टा पहिले
S&P 500, Nasdaq, Dow End Lower As Anthropic Trading Debut Fails To Provide Adequate Confidence — ANT, META, AAPL, GME In Focus
Traders Union
·
१ घण्टा पहिले
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
ChartMill
·
१ घण्टा पहिले
S&P 500 After-Hours Movers: Nov. 19, 2026
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB